Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
Open Access
- 15 December 2016
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Advances in Therapy
- Vol. 34 (2), 436-451
- https://doi.org/10.1007/s12325-016-0457-8
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionJournal of Diabetes Investigation, 2014
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureThe Lancet, 2013
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose ExcretionDiabetes Care, 2013
- Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNature Reviews Endocrinology, 2012
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010
- Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injuryClinical Science, 2008